GlaxoSmithKline PLC GSK sets new environmental goals (0736E)
03 Novembre 2020 - 09:00AM
UK Regulatory
TIDMGSK
RNS Number : 0736E
GlaxoSmithKline PLC
03 November 2020
Issued: GlaxoSmithKline plc, 3 November 2020, London UK
GSK sets new environmental goals of net zero impact on climate
and net positive impact on nature by 2030
Increasing scientific evidence [1] demonstrates that climate
change and nature loss are impacting the world and human health in
many ways, including: extreme heat contributing to deaths from
diseases; increased spread of infectious diseases and air pollution
exacerbating respiratory diseases.
Today, GSK has announced ambitious new environmental
sustainability goals in both climate and nature, aiming to have a
net zero impact on climate and a net positive impact on nature by
2030.
The new goals form part of GSK's Trust priority and ESG
approach, which support the company's aim to create long-term value
for shareholders and meet the needs of society. Over the next
decade, GSK will invest in measures to reduce its environmental
impact, in restoration programmes to balance the remaining impact
that the company cannot reduce and aim to put back into nature more
than the company takes out.
Underpinning these goals, the company has set new targets across
its different businesses, including: 100% renewable electricity
usage and good water stewardship at all GSK sites; 100% of
materials sustainably sourced and deforestation free and
transitioning to 100% usage of electric vehicles by GSK sales
representatives worldwide. More information on the goals and the
targets are available on gsk.com.
Emma Walmsley, Chief Executive Officer, GSK, said , "As a global
healthcare company, we want to play our full part in protecting and
restoring the planet's health, in order to protect and improve
people's health. Improving the environmental sustainability of our
business also makes us more resilient, protecting our operations,
so we can deliver the products that patients and consumers rely
on.
"As part of our Trust priority and ESG commitments, we are
announcing a new level of ambition on environmental sustainability,
with the twin goals of ensuring the new GSK has a net zero impact
on climate and a net positive impact on nature by 2030.
"All of us working at GSK are very motivated by the challenge of
delivering these new goals. Meeting these goals will require
working closely with others, including our suppliers, customers,
consumers and patients, and we are grateful for their support."
The new goals apply principally to GSK's Biopharma business and
portfolio. The company's Consumer Healthcare business will also
contribute towards these goals through delivery of its own targets,
whilst it is part of GSK. Post separation, the new Consumer Health
company will be a world-leading business and its new targets
reflect this, representing a significant new level of ambition, to
drive positive environmental change and help improve everyday
health.
GSK has long been committed to reducing its environmental impact
and was one of the first pharmaceutical companies to set ambitious
environment targets in 2010. Since then, across its operations GSK
has reduced carbon emissions by 34%, waste to landfill by 78% and
total water use by 31% (2019 figures).
The Science Based Targets Initiative has accredited that GSK's
new carbon targets align to a 1.5deg pathway - in line with the
most ambitious goal of the Paris Agreement. The company will align
to the Science Based Targets Network approach to measure its impact
on nature and will seek to accredit its nature target when the
methodology is finalised.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us .
GSK enquiries:
Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Tim Foley +44 (0) 20 8047 (London)
5502
Kristen Neese +1 804 217 8147 (Philadelphia)
Kathleen Quinn +1 202 603 5003 (Washington
DC)
Analyst/Investor Sarah Elton-Farr +44 (0) 20 8047 (London)
enquiries: 5194
Sonya Ghobrial +44 (0) 7392 (Consumer)
784784
Danielle Morris +44 (0) 20 8047 (London)
7562
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk Factors" in the company's Annual Report on Form 20-F for 2019
and as set out in GSK's "Principal risks and uncertainties" section
of the Q3 Results and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
[1] The 2019 report of the Lancet Countdown on health and
climate change ensuring that the health of a child born today is
not defined by a changing climate
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUOVBRRUUARRA
(END) Dow Jones Newswires
November 03, 2020 03:00 ET (08:00 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2023 a Mar 2024